-
If your clinical practice includes care of college-age youth, you will want to review the results of a new study of university students.
-
When it comes to HIV/AIDS, the nation's capitol is experiencing some of the highest rates in the United States. At least 3% of District of Columbia (DC) residents have HIV or AIDS, according to a 2009 epidemiology report by the DC HIV/AIDS office.
-
HIV-positive women have a much higher risk of developing cervical and uterine cancers than do women without the disease, due to their impaired immune function.
-
For women who request emergency contraception, ulipristal acetate might be an effective alternative to levonorgestrel, according to results of a new study.
-
Family planning clinicians are familiar with the hormones that regulate human reproduction. Research has identified a new hormone that suppresses reproduction, which opens the door to possible development of a new class of contraceptive.
-
In December 2009, the American College of Obstetricians and Gynecologists (ACOG ) released a clinical management guideline recommending changes to cervical cancer screening guidelines.
-
Look back to results of the 2004 Contraceptive Technology Update Contraception Survey: Just 30% of survey respondents said they inserted six or more intrauterine contraceptives in the past year.
-
This issue marks the 30th anniversary of Contraceptive Technology Update.
-
The next woman in your exam room says she has had cramping, breast tenderness, and headaches during the pill-free placebo week of her oral contraceptive (OC). She is open to having less frequent withdrawal bleeding. What's your next move?
-
When not constrained by your clinic's formulary, which oral contraceptive (OC) do you pick for a 21-year-old nonsmoking woman? Look to Ortho Tri-Cyclen Lo (Ortho-McNeil Pharmaceutical; Raritan, NJ), which continues its No. 1 spot in the 2009 Contraceptive Technology Update Contraception Survey.